Participated · Equity · Sep 2022

Saveo Healthtech is a Bengaluru-based B2B e-commerce platform that helps pharmacies address procurement and supply-chain issues. Founded in 2019 by Amit Kumar, Anurag Savarnya, Shivansh Shrivastava and Vivek Jaiswal, it serves over 12,000 outlets across Karnataka, Telangana and Tamil Nadu. The company recently raised $4.5 million in a fresh funding round that valued it at $50 million. Saveo plans to use the proceeds to expand its geographical footprint by setting up new units and to adopt advanced solutions to build a full-stack tech platform. Existing investors have continued to back the company as it scales its pharmacy-focused procurement offering. Saveo is a B2B managed marketplace that provides Indian pharmacies a single procurement point for all possible medicines. Founded in August 2019 by Amit Kumar, Anurag Savarnya, Shivansh Shrivastava, and Vivek Jaiswal, the company is based in Bengaluru. It operates as a managed marketplace servicing pharmacy procurement needs across India. Saveo plans to use the fresh funding to expand into newer and existing geographies. The company raised $4 million in a seed round co-led by Matrix Partners India and RTP Global, with participation from Incubate Fund, India Quotient, and angel investors. The article did not disclose operating metrics or revenue figures.

Participated · Series C · Nov 2021

Viome Life Sciences, based in Bellevue, WA and led by Founder and CEO Naveen Jain, focuses on longevity and preventative healthcare. The company leverages AI and algorithms to analyze gene expression data from over 600,000 samples to power at-home tests and personalized recommendations. Its product lineup includes custom-formulated supplements unique to each individual, personalized biotic blends for gut health, and oral biotic lozenges for oral microbiome health. Viome intends to deploy new capital toward research and development and retail expansion. Financially, it has raised a total of $175M to date after closing an $86.5M Series C. Investors in the most recent round include Khosla Ventures, Bold Capital, WRG Ventures and others. Viome Life Sciences is a Bellevue, WA-based systems biology company that uses biological data to help individuals improve their health. The company positions itself around systems-biology approaches to personalized health. Public reporting emphasizes its aim to translate biological insights into health-improvement offerings. Financially, Viome has been an active fundraiser, most recently securing a $54M pre-Series C convertible round. This follows a $56M Series B announced in November 2019 and brings total funding to date to over $125M. Returning and new investor participation has supported its continued operations and product development efforts.

Participated · Equity · Jun 2021

Heliogen develops the Sunlight Refinery™, a turnkey concentrated solar energy system that uses advanced computer vision software to precisely align mirrors and concentrate sunlight to very high temperatures (exceeding 1,000°C). The system is designed to deliver industrial-grade, near-24/7 carbon-free energy in the form of high-temperature heat, power (via a supercritical CO2 turbine), and green hydrogen (via electrolyzers). Heliogen positions the technology to replace fossil fuels in industrial processes such as cement, steel, and petrochemical production. The company was created at Idealab and has demonstrated commercial-scale temperatures and functionality. Heliogen has formed commercial partnerships and agreements, including a Memorandum of Understanding with Rio Tinto to deploy its technology at a borates mine in Boron, California. The company plans to use new funding to develop multiple Sunlight Refinery facilities initially in the United States and later in other solar-rich regions. Heliogen develops concentrated solar power plants that use supercritical carbon dioxide (sCO2) instead of steam to generate power, targeting much higher efficiency and smaller equipment footprint. The company plans to develop, build and operate an sCO2 power cycle integrated with thermal energy storage heated by a newly built heliostat field. Its technology is designed to produce ultra‑high temperatures above 1,000°C, enabling heat for hard‑to‑decarbonize industrial processes such as cement, steel and petrochemicals. Heliogen was launched in November 2019 and is backed by Bill Gates, Steve Case and Patrick Soon‑Shiong. The company recently received a $39 million grant from the U.S. Department of Energy to advance its sCO2 project and integrated thermal storage demonstration. The DOE award is part of a $130 million program funding 67 solar R&D projects, and Heliogen’s $39 million allocation was substantially larger than most other awards. Heliogen develops concentrated-solar thermal systems that it says can exceed 1,000°C, significantly higher than prior systems (~565°C) and sufficient for industrial heat and hydrogen production. The company aims to use concentrated sunlight to create and replace fossil fuels for industrial processes. Heliogen is led by Idealab founder and chairman Bill Gross and is working with partner Parsons on deployment. It has a pilot plant in Lancaster. Financially, Heliogen has attracted backing from notable investors including Bill Gates, Idealab, Neotribe and Dr. Patrick Soon-Shiong’s Nant Capital. As part of its recent funding, Neotribe’s founder Swaroop “Kittu” Kolluri and Dr. Soon-Shiong have joined Heliogen’s board.